Clinical trials: Irinotecan, completed
Pancreatic Cancer
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen.
- Trial name
- NCT03983057
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Zhejiang University
Colon Cancer, Primary Tumour
The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer
The clinical benefit of resection of the primary tumour in patients with synchronous unresectable metastases is not known. In the literature studies usually describe retrospective selected patients with synchronous metastases…
- Conditions
- Colon Cancer, Primary Tumour, Rectal Cancer
- Trial name
- CAIRO4 (NCT01606098)
- Testing
- Surgery of the primary tumour, Systemic treatment
- Where
- 46 sites in Denmark, Netherlands
- Volunteers
- 206 people
- Sponsor
- Dutch Colorectal Cancer Group
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Cancer
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Standard treatment for patients with diffuse pontine tumors is radiation therapy, but less than 10% of patients are cured. Adding standard chemotherapy has not improved the cure rate.
- Trial name
- NCT01012609
- Testing
- cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
- Where
- 12 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
- Trial name
- CC6 (NCT02118064)
- Testing
- G17DT-Irinotecan
- Volunteers
- 161 people
- Sponsor
- Cancer Advances Inc.
Advanced Solid Tumors
Study of ABT-700 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
- Trial name
- NCT01472016
- Testing
- ABT-700, docetaxel, FOLFIRI
- Volunteers
- 74 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Brain and Central Nervous System Tumors
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352521
- Testing
- bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Pancreatic Ductal Adenocarcinoma
Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only…
- Trial name
- NCT02440958
- Testing
- modified FOLFIRINOX regimen
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Pancreatic Cancer
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs.
- Trial name
- NCT02581215
- Testing
- mFOLFIRINOX, Ramucirumab
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Walid Shaib, MD
Lung Cancer
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182806
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
The purpose of the this study is to see if an investigations cancer treatment called vorinostat can be combined with the irinotecan/bevacizumab regimen safely.
- Trial name
- NCT00762255
- Testing
- Vorinostat, Bevacizumab, Irinotecan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results.
- Trial name
- NCT05583422
- Testing
- DPYD or UGT1A1 variants
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Colorectal Cancer
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and…
- Trial name
- NCT01116271
- Testing
- AZD6244, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
In Patients with metastatic colorectal cancer the following treatments first-line Folfiri+Cetuximab first-line Folfox6 + Cetuximab will be concerning efficacy and safety.
- Trial name
- NCT00286130
- Testing
- Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan, FOLFOX 6, FOLFIRI
- Where
- 27 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 150 people
- Sponsor
- Central European Cooperative Oncology Group
Unresectable or Metastatic Colorectal Cancer
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
- Trial name
- NCT00668863
- Testing
- FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil), Sunitinib
- Where
- 10 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Pfizer
Unspecified Childhood Solid Tumor, Protocol Specific
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or…
- Trial name
- NCT00016861
- Testing
- irinotecan hydrochloride
- Where
- United States
- Sponsor
- Texas Children's Cancer Center
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00008060
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Metastatic Biliary Tract Cancer
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
The purpose of this study is to evaluate the efficacy and safety of combination of fluorouracil/folinic acid and liposomal irinotecan(Onivyde) compared with fluoruracil/folinic acid in patients with metastatic biliary tract…
- Trial name
- NCT03524508
- Testing
- Onivyde, 5-FU/LV
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Changhoon Yoo
Brain and Central Nervous System Tumors
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006025
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- 9 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins